The evolution of cancer risk assessment in the era of next generation sequencing

Journal of Genetic Counseling

Volumn 23, Issue 4, 2014, Pages 633-639

  Fecteau, Heather ^a   Vogel, Kristen J ^b   Hanson, Kristen ^c   Morrill Cornelius, Shannon ^d  

^a Medical Center of Plano Trauma Services Department   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c ST JOSEPH MERCY HOSPITAL   (United States)

^d DANBURY HOSPITAL   (United States)

Author keywords

Genetic counseling; Genetic testing panels; Genetics; Hereditary; Medical; Neoplastic syndromes; Next generation sequencing

Indexed keywords

GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; INFORMED CONSENT; NEOPLASMS; PROCEDURES; RISK ASSESSMENT; SEQUENCE ANALYSIS;

GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INFORMED CONSENT; NEOPLASMS; RISK ASSESSMENT; SEQUENCE ANALYSIS;

EID: 84904252631     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-014-9714-7     Document Type: Article

References (30)

1. Ackerman, M. J.; Priori, S. G.; Willems, S.; Berul, C.; Brugada, R.; Calkins, H.; et al. (2011). HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm, 8(8), 1308-1339. doi: 10.1016/j.hrthm.2011.05.020.
2. ACMG Board of Directors. (2012). Points to consider in the clinical application of genomic sequencing. Genetics in Medicine, 14(8), 759-761. doi: 10.1038/gim.2012.74.
3. Ambry Lab. (2013). Retrived from http://www.ambrygen.com/sites/default/ files/pdfs/ACMG%20shared%20slides.pdf.
4. Birch, J. M.; Alston, R. D.; McNally, R. J.; Evans, D. G.; Kelsey, A. M.; Harris, M.; et al. (2001). Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene, 20(34), 4621-4628. doi: 10.1038/sj.onc.1204621.
5. Casadei, S.; Norquist, B. M.; Walsh, T.; Stray, S.; Mandell, J. B.; Lee, M. K.; et al. (2011). Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Research, 71(6), 2222-2229. doi: 10.1158/0008-5472.can-10-3958.
6. Chompret, A.; Brugieres, L.; Ronsin, M.; Gardes, M.; Dessarps-Freichey, F.; Abel, A.; et al. (2000). P53 germline mutations in childhood cancers and cancer risk for carrier individuals. British Journal of Cancer, 82(12), 1932-1937. doi: 10.1054/bjoc.2000.1167.
7. Domchek, S.; Weber, B. L. (2008). Genetic Variants of uncertain significance: flies in the ointment. Journal of Clinical Oncology, 26(1), 16-17. doi: 10.1200/JCO.2007.14.4154.
8. Domchek, S. M.; Bradbury, A.; Garber, J. E.; Offit, K.; Robson, M. E. (2013). Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? Journal of Clinical Oncology, 31(10), 1267-1270. doi: 10.1200/jco.2012.46.9403.
9. Erkko, H.; Xia, B.; Nikkila, J.; Schleutker, J.; Syrjakoski, K.; Mannermaa, A.; et al. (2007). A recurrent mutation in PALB2 in Finnish cancer families. Nature, 446(7133), 316-319. doi: 10.1038/nature05609.
10. Frank, B.; Hemminki, K.; Meindl, A.; Wappenschmidt, B.; Sutter, C.; Kiechle, M.; et al. (2007). BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study. BMC Cancer, 7, 83. doi: 10.1186/1471-2407-7-83.
11. Gonzalez, K. D.; Noltner, K. A.; Buzin, C. H.; Gu, D.; Wen-Fong, C. Y.; Nguyen, V. Q.; et al. (2009). Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. Journal of Clinical Oncology, 27(8), 1250-1256. doi: 10.1200/jco.2008.16.6959.
12. Halbert, C. H.; Stopfer, J. E.; McDonald, J.; Weathers, B.; Collier, A.; Troxel, A. B.; et al. (2011). Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns? Journal of Clinical Oncology, 29(32), 4302-4306. doi: 10.1200/jco.2010.33.1561.
13. Hamilton, J. G.; Lobel, M.; Moyer, A. (2009). Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychology, 28(4), 510-518. doi: 10.1037/a0014778.
14. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, "Genetic/Familial High-Risk Assessment: Breast and Ovarian," 2013, http://www.nccn.org/index.asp.
15. Jones, S.; Hruban, R. H.; Kamiyama, M.; Borges, M.; Zhang, X.; Parsons, D. W.; et al. (2009). Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science, 324(5924), 217. doi: 10.1126/science.1171202.
16. Kleihues, P.; Schauble, B.; Zur Hausen, A.; Esteve, J.; Ohgaki, H. (1997). Tumors associated with p53 germline mutations: a synopsis of 91 families. The American Journal of Pathology, 150(1), 1-13.
17. Lewis, A. G.; Flanagan, J.; Marsh, A.; Pupo, G. M.; Mann, G.; Spurdle, A. B.; et al. (2005). Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Research, 7(6), R1005-R1016. doi: 10.1186/bcr1336.
18. Li, F. P.; Fraumeni, J. F.; Jr.; Mulvihill, J. J.; Blattner, W. A.; Dreyfus, M. G.; Tucker, M. A.; et al. (1988). A cancer family syndrome in twenty-four kindreds. Cancer Research, 48(18), 5358-5362.
19. Meldrum, C.; Doyle, M. A.; Tothill, R. W. (2011). Next-generation sequencing for cancer diagnostics: a practical perspective. Clinical Biochemistry Reviews, 32(4), 177-195.
20. Nichols, K. E.; Malkin, D.; Garber, J. E.; Fraumeni, J. F.; Jr.; Li, F. P. (2001). Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiology, Biomarkers and Prevention, 10(2), 83-87.
21. Offit, K. (2011). Personalized medicine: new genomics, old lessons. Human Genetics, 130(1), 3-14. doi: 10.1007/s00439-011-1028-3.
22. Pletcher, B. A.; Toriello, H. V.; Noblin, S. J.; Seaver, L. H.; Driscool, D. A.; Bennett, R. L.; et al. (2007). Indications for genetic referral: a guide for health care professionals. Genetics in Medicine, 9(6), 385-389.
23. U.S. Preventive Services Task Force (2014). Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: Recommendations From the U.S. Preventive Services Task Force. Annals of Internal Medicine 160 (4), I-16-16.
24. Rafnar, T.; Gudbjartsson, D. F.; Sulem, P.; Jonasdottir, A.; Sigurdsson, A.; Jonasdottir, A.; et al. (2011). Mutations in BRIP1 confer high risk of ovarian cancer. Nature Genetics, 43(11), 1104-1107. doi: 10.1038/ng.955.
25. Rahman, N.; Seal, S.; Thompson, D.; Kelly, P.; Renwick, A.; Elliott, A.; et al. (2007). PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nature Genetics, 39(2), 165-167. doi: 10.1038/ng1959.
26. Rehm, H. L.; Bale, S. J.; Bayrak-Toydemir, P.; Berg, J. S.; Brown, K. K.; Deignan, J. L.; et al. (2013). ACMG clinical laboratory standards for next-generation sequencing. Genetics in Medicine, 15(9), 733-747. doi: 10.1038/gim.2013.92.
27. Robson, M. E.; Storm, C. D.; Weitzel, J.; Wollins, D. S.; Offit, K. (2010). American society of clinical oncology policy statement update: Genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893-901.
28. Seal, S.; Thompson, D.; Renwick, A.; Elliott, A.; Kelly, P.; Barfoot, R.; et al. (2006). Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nature Genetics, 38(11), 1239-1241. doi: 10.1038/ng1902.
29. Villani, A.; Tabori, U.; Schiffman, J.; Shlien, A.; Beyene, J.; Druker, H.; et al. (2011). Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. The Lancet Oncology, 12(6), 559-567. doi: 10.1016/s1470-2045(11)70119-x.
30. Walsh, T.; Casadei, S.; Lee, M. K.; Pennil, C. C.; Nord, A. S.; Thornton, A. M.; et al. (2011). Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 108(44), 18032-18037. doi: 10.1073/pnas.1115052108.